No, because the incentive to create medicines will be tied to health impact health impact and because health impact will be measured: remuneration rights are expected to bring more stability. By monitoring medicines effectiveness and illness spread, medicine demand will be more predictable while the current patent system is tied to sales, marketing and market demands, which makes it more volatile.
